October 29, 2015

Kite Pharma and Alpine Immune Sciences Announce Research Collaboration and License Agreement to Enhance Immune Response in the Tumor Microenvironment

October 27, 2015

Kite Pharma Initiates ZUMA-1 Phase 2 in Patients With Aggressive, Refractory Non-Hodgkin’s Lymphoma (NHL) to Support Registration of KTE-C19

October 27, 2015

Kite Pharma and Alpine Immune Sciences Announce Research Collaboration and License Agreement to Enhance Immune Response in the Tumor Microenvironment

October 21, 2015

Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains

October 15, 2015

Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE

October 15, 2015

Kite Pharma Receives Positive Opinions for Orphan Drug Designation in the European Union (EU) for KTE-C19 in Three Additional Hematological Indications

October 7, 2015

Kite Pharma Commends Steven A. Rosenberg, M.D., Ph.D., on the Prestigious Medal of Honor Award From the American Cancer Society

October 1, 2015

Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers

September 30, 2015

Capricor Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa

September 25, 2015

Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference

September 24, 2015

Arno Therapeutics’ AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients with Serious Bacterial Infections

September 24, 2015

Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs

September 19, 2015

Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs

September 19, 2015

Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Exposition

September 15, 2015

Franz B. Humer, Former Chairman and CEO of Roche Group, Appointed to Kite Pharma’s Board of Directors

September 14, 2015

AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015

September 14, 2015

Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)

September 11, 2015

Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Cancer T-Cell Immunotherapy

September 3, 2015

Kite Pharma Commends Honors Conferred to Scientific Advisory Board Members for Their Significant Contributions to Medicine

September 3, 2015

Kite Pharma to Participate in Upcoming Investor Conferences in September 2015

September 1, 2015

Arno Therapeutics to Present at 17th Annual Rodman & Renshaw Conference

August 18, 2015

Arno Therapeutics Receives Authorization to Proceed with Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer

August 17, 2015

Kite Pharma Provides Update on KTE-C19 Clinical Trial

August 14, 2015

Arno Therapeutics Reports Second Quarter 2015 Financial Results and Business Update

August 14, 2015

Kite Pharma to Hold Conference Call to Provide a Corporate Update on Monday, August 17, 2015